MEDI-565

N/A

Report date: 2026/03/19 16:46:59

Base Information

Drug NameMEDI-565
Drug Alias NameAnti-CEA BiTE mAbanti-CEA BiTECEA BiTE mAbMT-111AMG-211 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCD3 T-cell engagersCarcinoembryonic antigen related cell adhesion molecule 5 antagonists
TargetsCarcinoembryonic antigen related cell adhesion molecule 5T cell surface glycoprotein CD3
Therapy Area/IndicationsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune LlcAmgen Inc
Active IndicationsN/A
Inactive IndicationsGastrointestinal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A